ShareValue scores for 000813.SHE: Valuation 47, Quality 29, Growth 50, Health 44.

000813.SHE
SZSE

Dezhan HealthCare Co Ltd

CN¥3.43(+4.26%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
47
Fair Value
Price vs Value
Quality
29
Weak
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
44
Moderate
Financial Stability
Momentum
35
Bearish
Price Trend

Company Details

About

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, and oseltamivir phosphate capsules. It also involved in the provision of biopeptides, industrial hemp, and medical service business. Dezhan Healthcare Company Limited was founded in 1980 and is based in Beijing, the People's Republic of China. Address: First Shanghai Center, Beijing, China, 100025

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026